Trending...
- DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against JOYY, Inc. and Encourages Investors to Contact the Firm
- New Rochelle: Commercial Burglary- Three Suspects Sought
- YY Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds JOYY Inc. Investors of Class Action and Lead Plaintiff Deadline: January 19, 2021
NEW YORK--(BUSINESS WIRE)--IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on December 3, 2020, the Company granted a newly hired employee equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan. The inducement grants were approved by the Company's compensation committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to the employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of the employee's employment compensation.
The inducement grants consisted of a non-statutory option to purchase 34,000 shares of the Company's common stock, a grant of 7,000 restricted stock units for shares of the Company's common stock.
The stock option has an exercise price of $6.37 per share, equal to the closing price of IVERIC bio's common stock on December 3, 2020. The stock option has a ten year term and vests over four years, with 25% of the shares underlying the option vesting on December 3, 2021 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive month thereafter. The grant of 7,000 restricted stock units for shares of the Company's common stock vests with respect to 100% of the shares underlying the grant on December 3, 2021. The vesting of each grant is subject to the employees continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company's 2019 Inducement Stock Incentive Plan.
More on Nyenta.com
About IVERIC bio
IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.
ISEE-G
The inducement grants consisted of a non-statutory option to purchase 34,000 shares of the Company's common stock, a grant of 7,000 restricted stock units for shares of the Company's common stock.
The stock option has an exercise price of $6.37 per share, equal to the closing price of IVERIC bio's common stock on December 3, 2020. The stock option has a ten year term and vests over four years, with 25% of the shares underlying the option vesting on December 3, 2021 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive month thereafter. The grant of 7,000 restricted stock units for shares of the Company's common stock vests with respect to 100% of the shares underlying the grant on December 3, 2021. The vesting of each grant is subject to the employees continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company's 2019 Inducement Stock Incentive Plan.
More on Nyenta.com
- Edgemont Partners Advises Prescient Healthcare Group on Its investment by Bridgepoint
- SHAREHOLDER DEADLINE ALERT: WeissLaw LLP Reminds SolarWinds Corporation Shareholders About Its Ongoing Investigation
- Rustic Deco Launches B2B Wholesale Furniture Website
- New Rochelle: Applications Now Available for First Annual Little Hoopers Basketball Clinic
- Ponos Industries Extends Tender Offer for up to 2,000,000 Shares of Common Stock of Verizon Communications Inc
About IVERIC bio
IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.
ISEE-G
Filed Under: Business
0 Comments
Latest on Nyenta.com
- IOTech names Gavin Hunter as VP of global marketing
- One of the Last Remaining Sports Apparel Companies with Direct Lineage to the Negro Leagues Creates a Limited Edition Capsule to Celebrate the Centennial of The National Negro Leagues
- Introducing BIAMI.IO Apps Framework
- Tapestry, Inc. to Host FY21 Second Quarter Earnings Call
- K2 Sports Upgrades B2B eCommerce With Emerald's Elastic Suite Platform
- Announcement of Results of Tender Offer for Any and All 2024 Notes by Simpar Europe
- Rochester: Statement Regarding the Inauguration of President Biden and Vice President Harris
- EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against 9F Inc. – JFU
- Bonnie Fuller Assumes Full Ownership of Hollywood Life
- Mayor Mike Spano, Yonkers Public Schools Launch Rev. Dr. Martin Luther King, Jr. Video Contest
- Famer, Alliance Fastpitch Announce Multi-Year Partnership to Deliver Softball Training Curriculum
- Tracker Capital Acquires Presage Security
- Authentic Equity Acquisition Corp. Announces Closing of $230 Million Initial Public Offering of Securities Including Full Exercise of Overallotment Option
- Waste Management & NYC Department of Sanitation Presenting 4th Annual M/WBE Forum
- City Streaming TV, a Streaming Television Inc Network Launches, bringing Community and Faith Leaders into local TV's, At No Cost
- MetroPlusHealth Announces President and Chief Executive Officer Talya Schwartz, MD, Honored Again by City & State as One of New York City's 2021 "Health Power 100"
- Too Lost Gives Independent Musicians a New Option for Distributing and Marketing Their Music
- FEATURED RELEASE: "Everything" by S.P.O.T
- BoatDealers.ca Surges with Record Traffic in 2020
- Working is on at IBEX Packaging with all SOPs during Covid-19